Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Sales (2017 - 2025)

Historic Return on Sales for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to 1.21%.

  • UroGen Pharma's Return on Sales fell 2700.0% to 1.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.71%, marking a year-over-year decrease of 4100.0%. This contributed to the annual value of 1.4% for FY2024, which is 1700.0% down from last year.
  • As of Q3 2025, UroGen Pharma's Return on Sales stood at 1.21%, which was down 2700.0% from 2.06% recorded in Q2 2025.
  • UroGen Pharma's 5-year Return on Sales high stood at 0.94% for Q3 2024, and its period low was 3.46% during Q1 2021.
  • Its 5-year average for Return on Sales is 1.74%, with a median of 1.61% in 2022.
  • In the last 5 years, UroGen Pharma's Return on Sales skyrocketed by 48323700bps in 2021 and then crashed by -5300bps in 2025.
  • UroGen Pharma's Return on Sales (Quarter) stood at 1.76% in 2021, then increased by 9bps to 1.6% in 2022, then skyrocketed by 31bps to 1.11% in 2023, then tumbled by -38bps to 1.53% in 2024, then increased by 21bps to 1.21% in 2025.
  • Its Return on Sales stands at 1.21% for Q3 2025, versus 2.06% for Q2 2025 and 2.16% for Q1 2025.